NRG1 fusions in breast cancer

BACKGROUND: NRG1 gene fusions may be clinically actionable, since cancers carrying the fusion transcripts can be sensitive to tyrosine kinase inhibitors. The NRG1 gene encodes ligands for the HER2(ERBB2)-ERBB3 heterodimeric receptor tyrosine kinase, and the gene fusions are thought to lead to autocr...

Descripción completa

Detalles Bibliográficos
Autores principales: Howarth, Karen D., Mirza, Tashfina, Cooke, Susanna L., Chin, Suet-Feung, Pole, Jessica C., Turro, Ernest, Eldridge, Matthew D., Garcia, Raquel Manzano, Rueda, Oscar M., Boursnell, Chris, Abraham, Jean E., Caldas, Carlos, Edwards, Paul A. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788813/
https://www.ncbi.nlm.nih.gov/pubmed/33413557
http://dx.doi.org/10.1186/s13058-020-01377-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788813/
https://www.ncbi.nlm.nih.gov/pubmed/33413557
http://dx.doi.org/10.1186/s13058-020-01377-5

Ejemplares similares